€1.55
0.85% today
L&S, Jun 28, 08:04 pm CET
ISIN
NL0010872495
Symbol
PRQR
Sector
Industry

ProQR Therapeutics N.V. Share price

$1.65
-0.23 12.23% 1M
-0.36 17.91% 6M
-0.33 16.67% YTD
-0.01 0.60% 1Y
-5.32 76.33% 3Y
-7.97 82.85% 5Y
-13.08 88.80% 10Y
Nasdaq, Closing price Thu, Jun 27 2024
ISIN
NL0010872495
Symbol
PRQR
Sector
Industry

Key figures

Market capitalization $134.74m
Enterprise Value $42.99m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.85
P/S ratio (TTM) P/S ratio 12.07
P/B ratio (TTM) P/B ratio 3.58
Sales growth (TTM) Sales growth 210.56%
Turnover (TTM) Turnover $11.16m
EBIT (operating result TTM) EBIT $-36.56m
Free cash flow (TTM) Free cash flow $-43.36m
Cash position $110.93m
EPS (TTM) EPS $-0.36
P/E ratio expected negative
P/S ratio expected 5.69
EV/Sales expected 1.82
Short interest 0.34%
Show more

Is ProQR Therapeutics N.V. a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

ProQR Therapeutics N.V. Share analysis

Unlock scores for free

Analyst opinions

6 Analysts have issued a ProQR Therapeutics N.V. forecast:

5x Buy
83%
1x Hold
17%

Analyst opinions

6 Analysts have issued a ProQR Therapeutics N.V. forecast:

Buy
83%
Hold
17%

Financial data from ProQR Therapeutics N.V.

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
11 11
211% 211%
100%
- Direct costs - -
-
-
- -
-
-
- Selling and administrative expenses 11 11
16% 16%
101%
- Research and development costs 31 31
32% 32%
276%
-34 -34
41% 41%
-302%
- Depreciation and amortization 2.88 2.88
11% 11%
26%
EBIT (operating result) EBIT -37 -37
39% 39%
-328%
Net profit -29 -29
53% 53%
-261%

Figures in millions USD.

Don't miss a thing! We will send you all news about the ProQR Therapeutics N.V. share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

ProQR Therapeutics N.V. Share News

Neutral
Seeking Alpha
about 2 months ago
ProQR Therapeutics N.V. (NASDAQ:PRQR ) ASGCT Investor Webcast May 9, 2024 8:00 AM ET Company Participants Sarah Kiely - IR Daniel de Boer - Founder and CEO Gerard Platenburg - Chief Scientific Officer Conference Call Participants Jon Wolleben - Citizens JMP Steve Seedhouse - Raymond James Sarah Kiely Thank you, and good day, everyone.
Neutral
GlobeNewsWire
about 2 months ago
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) --  ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2024, and provided a business update.
Neutral
GlobeNewsWire
2 months ago
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Wednesday, May 22, 2024 at 1630 CET (10:30am EDT)...
More ProQR Therapeutics N.V. News

Company profile

ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Head office Netherlands
CEO Daniel Boer
Employees 156
Founded 2012
Website www.proqr-tx.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now